1-5 of 5
Jason C. Paik
Close
Sort by
Journal Articles

Broad Superiority of Zanubrutinib (Zanu) Over Bendamustine + Rituximab (BR) Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)

Vanitha Ramakrishnan, Linlin Xu, Jason C. Paik, Carol Marimpietri, Eric Shen, Xiaoxi Dong, Jessica Li, Andreas Agathangelidis, Tian Tian, Aileen Cleary Cohen, Tadeusz Robak, Constantine S. Tam, Paolo Ghia, Andrew Rawstron, Jennifer R. Brown
Journal: Blood
Blood (2023) 142 (Supplement 1): 1902.
https://doi.org/10.1182/blood-2023-174543
Published: 2023
Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial

Alessandra Tedeschi, Emmanuelle Ferrant, Ian W. Flinn, Constantine S. Tam, Paolo Ghia, Tadeusz Robak, Jennifer R. Brown, Vanitha Ramakrishnan, Tian Tian, Sowmya B. Kuwahara, Jason C. Paik, Aileen Cohen, Jane Huang, Peter Hillmen
Journal: Blood
Blood (2021) 138 (Supplement 1): 67.
https://doi.org/10.1182/blood-2021-144336
Published: 2021
Journal Articles

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Constantine S. Tam, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Tian Tian, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen
Journal: Blood
Blood (2021) 138 (Supplement 1): 396.
https://doi.org/10.1182/blood-2021-148457
Published: 2021
Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Jennifer R. Brown, MD PhD, Tadeusz Robak, MDPhD, Paolo Ghia, MD PhD, Brad S. Kahl, MD, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Wojciech Janowski, MBChB, FRCPA, FRACP, Henry Chan, MBChB, FRACP, FRCPA, Mazyar Shadman, MD MPH, Peter S. Ganly, BMBCh, PhD, Luca Laurenti, MD, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Monica Tani, MD, Hanna Ciepluch, MD, Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Martin Šimkovič, MD PhD, Anders Österborg, MD PhD, Marek Trněný, MD, Alessandra Tedeschi, MD, Piers Blombery, MBBS, Jason C. Paik, MD PhD, Fangfang Yin, PhD, Shibao Feng, PhD, Vanitha Ramakrishnan, PhD, Jane Huang, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, Constantine S. Tam, MBBS, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-134280
Published: 2020
Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Constantine S. Tam, MBBS, MD, Ian W. Flinn, MD PhD, Alessandra Tedeschi, MD, Emmanuelle Ferrant, MD, Jennifer R. Brown, MD PhD, Tadeusz Robak, MDPhD, Paolo Ghia, MD PhD, Sowmya B. Kuwahara, PharmD, Jason C. Paik, MD PhD, Lei Hua, PhD, Aileen Cohen, MD PhD, Jane Huang, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-134179
Published: 2020